Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.6K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

6.5K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
6.5K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aging dictates tumor-specific genomic alterations across cancer types.

npj aging·2026
Same author

Design and implementation of an end-to-end AI-driven colonoscopy recall workflow at scale.

JAMIA open·2026
Same author

Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.

Clinical genitourinary cancer·2026
Same author

ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Single-cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.

NPJ precision oncology·2025
Same author

Single Cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Mar 11, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.6K

Polycythemia and Thrombocytosis.

Aric Parnes1, Arvind Ravi2

  • 1Division of Hematology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

Primary Care
|November 22, 2016
PubMed
Summary

Myeloproliferative neoplasms (MPNs) involve excess bone marrow cell growth, including polycythemia vera (PV) and essential thrombocytosis (ET). Management focuses on preventing blood clots and bleeding, with risks of progression to serious conditions.

Keywords:
Essential thrombocytosisJAK2 mutationMyelofibrosisMyeloproliferative neoplasmsPolycythemia vera

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.9K

Related Experiment Videos

Last Updated: Mar 11, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.6K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.9K

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myeloproliferative neoplasms (MPNs) are clonal bone marrow stem cell disorders characterized by the overproduction of one or more mature blood cell types.
  • Classic MPNs include polycythemia vera (PV) and essential thrombocytosis (ET), involving excess red blood cells and platelets, respectively.
  • These conditions share overlapping mutations in growth factor signaling pathways, leading to similar clinical features and management strategies.

Purpose of the Study:

  • To summarize the key characteristics, clinical presentations, and management principles of myeloproliferative neoplasms.
  • To highlight the shared features and distinct cellular origins of polycythemia vera and essential thrombocytosis.
  • To outline the potential complications and prognostic implications of MPNs.

Main Methods:

  • Literature review of classic and current research on myeloproliferative neoplasms.
  • Analysis of clinical data pertaining to polycythemia vera and essential thrombocytosis.
  • Synthesis of information regarding disease progression and management strategies.

Main Results:

  • PV and ET are distinct MPNs with shared clinical features due to common signaling pathway mutations.
  • Management strategies for PV and ET primarily aim to mitigate thrombotic and hemorrhagic risks.
  • Both PV and ET carry a risk of transformation into myelofibrosis or acute myeloid leukemia.

Conclusions:

  • MPNs, including PV and ET, require careful management to prevent complications and monitor for disease progression.
  • Understanding the shared and distinct aspects of these neoplasms is crucial for effective patient care.
  • Early identification and intervention are key to improving outcomes in patients with MPNs.